-
Chiralix, a Symeres company
At Symeres, many passionate scientists are engaged in R&D projects with […]
-
C&ENs 10 Start-Ups to Watch
This week, the 2021 Chemical & Engineering News list of ‘10 […]
-
Expanding the toolbox: Resolving racemates
Symeres has quite a legacy when it comes to university collaborations. […]
-
From CRO client to CRO employee: An interview with Dr. Chris Teleha
While working in big pharma, Dr. Chris Teleha spent years working with CROs […]
-
On the road again: Experiencing BioTrinity 2021 as our first 2021 live event
COVID-19 has changed how we interact with people and has forced […]
-
The ‘Art of API’
In their book, The Logic of Chemical Synthesis, E. J. Corey and Xue-Min […]
-
Renewal of the GMP certificate for Symeres Prague
This spring, Symeres Prague was audited by the national control authority […]
-
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
Earlier this year, our client TOLREMO therapeutics nominated the clinical candidate […]
-
Symeres joins forces with Keensight Capital
Paris (France) – May 25th 2021 We are pleased to let […]
-
Excellent HTS hits by design, not by accident
The identification of tractable chemical starting points in the drug discovery […]
-
A follow-up on the European Lead Factory: The Symegold library
Delivery of an innovative 80,000 compound lead-like library for HTS and […]
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
